Arcturus therapeutics announces positive interim arct-021 (lunar-cov19) phase 1/2 study results for both single shot and prime-boost regimens, and up to $220 million in additional financial commitments from singapore

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics announces interim arct-021 phase 1/2 study results, and up to $220 million in additional financial commitments from singapore
ARCT Ratings Summary
ARCT Quant Ranking